HRTX Cash-Secured Put Strategy

HRTX (Heron Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014.

HRTX (Heron Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $144.4M, a beta of 1.71 versus the broader market, a 52-week range of 0.74-2.3, average daily share volume of 2.2M, a public-listing history dating back to 1987, approximately 122 full-time employees. These structural characteristics shape how HRTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.71 indicates HRTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a cash-secured put on HRTX?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

Current HRTX snapshot

As of May 15, 2026, spot at $0.85, ATM IV 168.40%, IV rank 33.91%, expected move 48.28%. The cash-secured put on HRTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this cash-secured put structure on HRTX specifically: HRTX IV at 168.40% is mid-range versus its 1-year history, so the credit collected on a HRTX cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 48.28% (roughly $0.41 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HRTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on HRTX should anchor to the underlying notional of $0.85 per share and to the trader's directional view on HRTX stock.

HRTX cash-secured put setup

The HRTX cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HRTX near $0.85, the first option leg uses a $0.81 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HRTX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HRTX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Sell 1Put$0.81N/A

HRTX cash-secured put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

HRTX cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on HRTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on HRTX

Cash-secured puts on HRTX earn premium while a trader waits to acquire HRTX stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning HRTX.

HRTX thesis for this cash-secured put

The market-implied 1-standard-deviation range for HRTX extends from approximately $0.44 on the downside to $1.26 on the upside. A HRTX cash-secured put lets a trader earn premium while waiting to acquire HRTX at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current HRTX IV rank near 33.91% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on HRTX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, HRTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HRTX-specific events.

HRTX cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HRTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HRTX alongside the broader basket even when HRTX-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on HRTX carry tail risk when realized volatility exceeds the implied move; review historical HRTX earnings reactions and macro stress periods before sizing. Always rebuild the position from current HRTX chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on HRTX?
A cash-secured put on HRTX is the cash-secured put strategy applied to HRTX (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With HRTX stock trading near $0.85, the strikes shown on this page are snapped to the nearest listed HRTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are HRTX cash-secured put max profit and max loss calculated?
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the HRTX cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 168.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a HRTX cash-secured put?
The breakeven for the HRTX cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current HRTX market-implied 1-standard-deviation expected move is approximately 48.28%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a cash-secured put on HRTX?
Cash-secured puts on HRTX earn premium while a trader waits to acquire HRTX stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning HRTX.
How does current HRTX implied volatility affect this cash-secured put?
HRTX ATM IV is at 168.40% with IV rank near 33.91%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related HRTX analysis